دورية أكاديمية

Cost-effectiveness of using protons for breast irradiation aiming at minimizing cardiotoxicity: A risk-stratification analysis

التفاصيل البيبلوغرافية
العنوان: Cost-effectiveness of using protons for breast irradiation aiming at minimizing cardiotoxicity: A risk-stratification analysis
المؤلفون: Guo Li, Yun-Fei Xia, Yi-Xiang Huang, Deniz Okat, Bo Qiu, Jerome Doyen, Pierre-Yves Bondiau, Karen Benezery, Jin Gao, Chao-Nan Qian
المصدر: Frontiers in Medicine, Vol 9 (2022)
بيانات النشر: Frontiers Media S.A., 2022.
سنة النشر: 2022
المجموعة: LCC:Medicine (General)
مصطلحات موضوعية: proton beam therapy, breast cancer, cost-effectiveness analysis, ischemic heart disease, Markov model, Medicine (General), R5-920
الوصف: BackgroundIncidental exposure of the heart to ionizing irradiation is associated with an increased risk of ischemic heart disease and subsequent fatality in patients with breast cancer after radiotherapy. Proton beam therapy can limit the heart dose in breast irradiation to a negligible level. However, compared with conventional photon modality, proton breast irradiation is more expensive. In this study, we performed cost-effectiveness analyses to identify the type of patients who would be more suitable for protons.MethodsA Markov decision model was designed to evaluate the cost-effectiveness of protons vs. photons in reducing the risk of irradiation-related ischemic heart disease. A baseline evaluation was performed on a 50-year-old woman patient without the preexisting cardiac risk factor. Furthermore, risk-stratification analyses for photon mean heart dose and preexisting cardiac risk were conducted on 40-, 50-, and 60-year-old women patients under different proton cost and willingness-to-pay (WTP) settings.ResultsUsing the baseline settings, the incremental effectiveness (protons vs. photons) increased from 0.043 quality-adjusted life-year (QALY) to 0.964 QALY when preexisting cardiac risk increased to 10 times its baseline level. At a proton cost of 50,000 US dollars ($), protons could be cost-effective for ≤ 60-year-old patients with diabetes and ≤50-year-old patients with grade II–III hypertension at the WTP of China ($37,653/QALY); for ≤ 60-year-old patients with diabetes and ≤ 50-year-old patients with grade II–III hypertension or ≥ 2 major cardiac risk factors at a WTP of $50,000/QALY; and for ≤ 60-year-old patients with diabetes, grade II–III hypertension or ≥ 2 major cardiac risk factors and ≤ 50-year-old patients with total cholesterol ≥ 240 mg/dL at a WTP of $100,000/QALY.ConclusionPatients' preexisting cardiac risk status was a key factor affecting the cardiac benefits gained from protons and should therefore be a major consideration for the clinical decision of using protons; cost-effective scenarios of protons exist in those patients with high risk of developing cardiac diseases.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2296-858X
Relation: https://www.frontiersin.org/articles/10.3389/fmed.2022.938927/full; https://doaj.org/toc/2296-858X
DOI: 10.3389/fmed.2022.938927
URL الوصول: https://doaj.org/article/1fee29ed3f8147439af362dda125139c
رقم الأكسشن: edsdoj.1fee29ed3f8147439af362dda125139c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2296858X
DOI:10.3389/fmed.2022.938927